Athersys to cut up to 70% of its workers in effort to survive By: Cleveland Business Journal via Business Journals June 02, 2022 at 18:35 PM EDT Athersys has been developing its MultiStem adult stem cell therapy since 1994 but has a hard time commercializing it. Read More >> Related Stocks: Harbor Disruptive Innovation ETF
